Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Calidi Biotherapeutics, Inc. (CLDI) had Normalized Income after Taxes of $-5.06M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-4.99M |
|
-- |
|
-- |
|
$5.06M |
|
$-5.06M |
|
$0.00M |
|
$-5.06M |
|
$-5.06M |
|
$-5.06M |
|
$-5.06M |
|
$-5.06M |
|
|
Normalized Income after Taxes |
$-5.06M |
$-5.06M |
|
$-4.67M |
|
27.09M |
|
27.09M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$11.49M |
|
$0.80M |
|
$3.58M |
|
$15.06M |
|
$5.43M |
|
$0.73M |
|
$2.34M |
|
$7.76M |
|
$7.30M |
|
$7.30M |
|
$7.30M |
|
31.79M |
|
| Cash Flow Statement Financials | |
$-7.13M |
|
$-0.01M |
|
$8.11M |
|
$9.81M |
|
$10.78M |
|
$0.97M |
|
$0.61M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.12 |
|
-- |
|
-- |
|
0.09 |
|
0.26 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-69.35% |
|
-69.35% |
|
-33.60% |
|
-63.05% |
|
$0.23 |
|
$-0.26 |
|
$-0.26 |
|